200
Participants
Start Date
August 15, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
May 31, 2027
Sacubitril, Valsartan 97-103 mg Oral Tablet
The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
Valsartan 160 mg
The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
Intravenous Glucose Tolerance Test
An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
Standardized Meals
Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
Exercise capacity VO2 maximum determination
Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
RECRUITING
University of Alabama at Birmingham, Birmingham
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Alabama at Birmingham
OTHER